Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy

Lupus

Volumn 21, Issue 8, 2012, Pages 914-918

  Tsai, M J ^a   Chou, C W ^b,c   Lin, F C ^a,c   Chang, S C ^a,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b TAIPEI MUNICIPAL GAN DAU HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Opportunistic infection; Pneumocystis jiroveci pneumonia; rituximab; systemic lupus erythematosus

Indexed keywords

AZITHROMYCIN; CASPOFUNGIN; CD20 ANTIGEN; CEFPIROME; CEFTRIAXONE; CEFUROXIME; CLINDAMYCIN; CYCLOSPORIN; FLOMOXEF; IMIPENEM; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRIMAQUINE; RITUXIMAB;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CASE REPORT; CAUSE OF DEATH; CHILL; COUGHING; DRUG EFFICACY; DRUG SUBSTITUTION; DYSPNEA; FEMALE; FEVER; HUMAN; IMMUNOCOMPROMISED PATIENT; LUNG INFILTRATE; LYMPHOMA; NONHUMAN; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; YOUNG ADULT;

EID: 84861830325     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312436855     Document Type: Article

References (15)

1. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004 ; 350: 2487-2498
2. Ramos-Casals M, García-Hernández FJ, de Ramón E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010 ; 28: 468-476
3. Catapano F, Chaudhry AN, Jones RB, Smith KG, Jayne DW. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2010 ; 25: 3586-3592
4. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010 ; 62: 2458-2466
5. Lertnawapan R, Totemchokchyakarn K, Nantiruj K, Janwityanujit S. Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol Int. 2009 ; 29: 491-496
6. Kamel S, O'Connor S, Lee N, Filshie R, Nandurkar H, Tam CS. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma. 2010 ; 51: 797-801
7. Teichmann LL, Woenckhaus M, Vogel C, Salzberger B, Scholmerich J, Fleck M. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford). 2008 ; 47: 1256-1257
8. Hugle B, Solomon M, Harvey E, et al. Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care Res (Hoboken). 2010 ; 62: 1661-1664
9. Kumar D, Gourishankar S, Mueller T, Cockfield S, Weinkauf J, Vethanayagam D, et al. Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. Transpl Infect Dis. 2009 ; 11: 167-170
10. Marcotte H, Lévesque D, Delanay K, et al. Pneumocystis carinii infection in transgenic B cell-deficient mice. J Infect Dis. 1996 ; 173: 1034-1037
11. Lund FE, Hollifield M, Schuer K, Lines JL, Randall TD, Garvy BA. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol. 2006 ; 176: 6147-6154
12. Wilk E, Witte T, Marquardt N, Horvath T, et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum. 2009 ; 60: 3563-3571
13. Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma. 2007 ; 48: 1307-1312
14. Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol. 1996 ; 23: 1186-1188
15. Turner-Stokes T, Lu TY, Ehrenstein MR, Giles I, Rahman A, Isenberg DA. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford). 2011 ; 50: 1401-1408